why Plus Therapeutics Inc. [PSTV] is a Good Choice for Investors After New Price Target of $3.50

Plus Therapeutics Inc. [NASDAQ: PSTV] jumped around 0.07 points on Thursday, while shares priced at $0.55 at the close of the session, up 14.69%. The company report on October 6, 2022 that Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2022 financial results on Thursday, October 20, 2022, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Plus Therapeutics Inc. stock is now -48.10% down from its year-to-date (YTD) trading value. PSTV Stock saw the intraday high of $0.574 and lowest of $0.48 per share. The company’s 52-week high price is 2.16, which means current price is +39.71% above from all time high which was touched on 01/04/22.

Compared to the average trading volume of 4.09M shares, PSTV reached a trading volume of 2133358 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Plus Therapeutics Inc. [PSTV]?

Ladenburg Thalmann have made an estimate for Plus Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 25, 2021. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on October 16, 2020, representing the official price target for Plus Therapeutics Inc. stock.

The Average True Range (ATR) for Plus Therapeutics Inc. is set at 0.07 The Price to Book ratio for the last quarter was 1.27, with the Price to Cash per share for the same quarter was set at 0.52.

How has PSTV stock performed recently?

Plus Therapeutics Inc. [PSTV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.54. With this latest performance, PSTV shares dropped by -28.15% in over the last four-week period, additionally sinking by -44.95% over the last 6 months – not to mention a drop of -69.03% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PSTV stock in for the last two-week period is set at 48.34, with the RSI for the last a single of trading hit 54.15, and the three-weeks RSI is set at 47.37 for Plus Therapeutics Inc. [PSTV]. The present Moving Average for the last 50 days of trading for this stock 0.6139, while it was recorded at 0.4746 for the last single week of trading, and 0.7649 for the last 200 days.

Plus Therapeutics Inc. [PSTV]: Deeper insight into the fundamentals

Return on Equity for this stock declined to -193.25, with Return on Assets sitting at -78.62.

Plus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 2.70.

Insider trade positions for Plus Therapeutics Inc. [PSTV]

There are presently around $2 million, or 11.00% of PSTV stock, in the hands of institutional investors. The top three institutional holders of PSTV stocks are: PARKMAN HEALTHCARE PARTNERS LLC with ownership of 1,533,075, which is approximately 0.443% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 855,264 shares of the stock with an approximate value of $0.47 million in PSTV stocks shares; and OTTER CREEK ADVISORS, LLC, currently with $0.18 million in PSTV stock with ownership of nearly 293.521% of the company’s market capitalization.

Positions in Plus Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 10 institutional holders increased their position in Plus Therapeutics Inc. [NASDAQ:PSTV] by around 403,706 shares. Additionally, 5 investors decreased positions by around 95,239 shares, while 10 investors held positions by with 3,067,558 shares. The mentioned changes placed institutional holdings at 3,566,503 shares, according to the latest SEC report filing. PSTV stock had 3 new institutional investments in for a total of 80,089 shares, while 1 institutional investors sold positions of 10,942 shares during the same period.


Please enter your comment!
Please enter your name here